These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 10583526)

  • 1. Hemophilia. Treatment of patients with inhibitors: cost issues.
    Goudemand J
    Haemophilia; 1999 Nov; 5(6):397-401. PubMed ID: 10583526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.
    Mehta DA; Oladapo AO; Epstein JD; Novack AR; Neufeld EJ; Hay JW
    J Manag Care Spec Pharm; 2016 Feb; 22(2):149-57. PubMed ID: 27015254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost and effectiveness of treatments for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Korea.
    You CW; Lee SY; Park SK
    Haemophilia; 2009 Jan; 15(1):217-26. PubMed ID: 18754800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-utility analysis of recombinant factor VIIa (NovoSeven) in six children with long-standing inhibitors to factor VIII or IX.
    Ekert H; Brewin T; Boey W; Davey P; Tilden D
    Haemophilia; 2001 May; 7(3):279-85. PubMed ID: 11380632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs and utilization of hemophilia A and B patients with and without inhibitors.
    Armstrong EP; Malone DC; Krishnan S; Wessler MJ
    J Med Econ; 2014 Nov; 17(11):798-802. PubMed ID: 25111634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling.
    Ballal RD; Botteman MF; Foley I; Stephens JM; Wilke CT; Joshi AV
    Curr Med Res Opin; 2008 Mar; 24(3):753-68. PubMed ID: 18234151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors.
    Knight C; Danø AM; Kennedy-Martin T
    Haemophilia; 2009 Mar; 15(2):405-19. PubMed ID: 19187191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exposure and safety of higher doses of recombinant factor VIIa ≥250 μg kg(-1) in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004-2008).
    Neufeld EJ; Kessler CM; Gill JC; Wilke CT; Cooper DL;
    Haemophilia; 2011 Jul; 17(4):650-6. PubMed ID: 21299750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
    Parameswaran R; Shapiro AD; Gill JC; Kessler CM;
    Haemophilia; 2005 Mar; 11(2):100-6. PubMed ID: 15810910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high-responding inhibitors.
    Smith OP
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():22-5. PubMed ID: 12214142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of inhibitors on the cost of clotting factor replacement therapy in Haemophilia A in Canada.
    Chang H; Sher GD; Blanchette VS; Teitel JM
    Haemophilia; 1999 Jul; 5(4):247-52. PubMed ID: 10469178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
    Scharrer I
    Haemophilia; 1999 Jul; 5(4):253-9. PubMed ID: 10469179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant factor VIIa versus aPCCs in haemophiliacs with inhibitors: treatment and cost considerations.
    Teitel JM
    Haemophilia; 1999 Sep; 5 Suppl 3():43-9. PubMed ID: 10597387
    [No Abstract]   [Full Text] [Related]  

  • 14. Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec registry.
    Salaj P; Kubes R; Cetkovsky P; Capova I; Penka M; Ovesná P; Mesterton J; Lindgren P
    Thromb Res; 2014 Feb; 133(2):162-7. PubMed ID: 24321420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Working group of hematology experts from Australia and New Zealand, Melbourne, April 2011.
    Brown SA; Barnes C; Curtin J; Dunkley S; Ockelford P; Phillips J; Rowell J; Smith M; Tran H;
    Intern Med J; 2012 Nov; 42(11):1243-50. PubMed ID: 23157518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic impact of treating inhibitor patients.
    Lacey L
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():29-32. PubMed ID: 12214144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: haemophilia registry data from the Czech Republic.
    Salaj P; Penka M; Smejkal P; Geierova V; Ovesná P; Brabec P; Cetkovsky P; Kubes R; Mesterton J; Lindgren P
    Thromb Res; 2012 May; 129(5):e233-7. PubMed ID: 22386136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations.
    Jiménez-Yuste V; Alvarez MT; Martín-Salces M; Quintana M; Rodriguez-Merchan C; Lopez-Cabarcos C; Velasco F; Hernández-Navarro F
    Haemophilia; 2009 Jan; 15(1):203-9. PubMed ID: 19149850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registries.
    Shapiro AD; Neufeld EJ; Blanchette V; Salaj P; Gut RZ; Cooper DL
    Haemophilia; 2014 Jan; 20(1):e23-31. PubMed ID: 24354484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection.
    Chuansumrit A; Isarangkura P; Angchaisuksiri P; Sriudomporn N; Tanpowpong K; Hathirat P; Jorgensen LN
    Haemophilia; 2000 Mar; 6(2):61-5. PubMed ID: 10781189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.